贝伐珠单抗与安罗替尼联合奥沙利铂治疗晚期直肠癌的临床疗效 [中文引用][英文引用]

【摘要】目的：评估贝伐珠单抗与安罗替尼分别联合奥沙利铂方案治疗晚期直肠癌的临床疗效。方法：回顾性分析2019年1月至2021年1月承德市中医院收治的晚期直肠癌患者88例，根据患者使用的治疗方案，分为对照组（贝伐珠单抗联合奥沙利铂治疗）47例、观察组（安罗替尼联合奥沙利铂治疗）41例。观察比较两组患者治疗后的临床疗效、血清肿瘤标志物（CEA、CA19-9）水平和生命质量，以及治疗期间的不良反应发生率。随访2年，观察两组患者的生存情况。结果：治疗后，观察组客观缓解率（ORR）为46.34%，病情控制率（DCR）为78.05%，均显著高于对照组（ORR25.53%，DCR57.45%，P<0.05）。治疗后两组患者血清肿瘤标志物CEA、CA19-9均明显改善，观察组改善程度优于对照组（P<0.001）。2年随访，观察组的中位无进展生存期（PFS）为（19.88±5.12）个月，显著长于对照组的（16.91±6.06）个月（P<0.05）。在生活质量方面，观察组的生理状况、家庭/社会状况、情感状况、功能状况和附加关注评分均显著高于对照组（P <0.05）。此外，两组患者治疗期间的不良反应发生率无显著差异（P >0.05）。结论：安罗替尼联合奥沙利铂较贝伐珠单抗联合奥沙利铂治疗晚期直肠癌临床疗效更显著，可进一步延长患者中位PFS，提高生活质量。

 [Abstract]  Objective  To evaluate the clinical efficacy of bevacizumab and anlotinib combined with oxaliplatin in the treatment of advanced rectal cancer. Methods  A retrospective analysis was conducted on 88 patients with advanced rectal cancer admitted from January 2019 to January 2021. Patients were categorized into two groups based on their treatment regimens: the control group (treated with bevacizumab combined with oxaliplatin, n=47) and the observation group (treated with anlotinib combined with oxaliplatin, n=41). Clinical efficacy after treatment, serum tumor markers (CEA and CA19-9) levels, quality of life, and adverse reaction incidence were compared between the two groups. Both groups were also followed up for 2 years to observe survival status. Results  After treatment, the objective response rate (ORR) of the observation group was 46.34%, and the disease control rate (DCR) was 78.05%, both significantly higher than those of the control group (ORR 25.53% and DCR 57.45%, P<0.05). After treatment, serum tumor markers CEA and CA19-9 both showed significant improvement, and the improvement in the observation group was significantly better than that in the control group (P<0.001). During the 2-year follow-up period, the median progression-free survival (PFS) of the observation group was (19.88±5.12) months, significantly longer than that of the control group, which was (16.91±6.06) months (P<0.05). In terms of quality of life, the scores of physical condition, family/social situation, emotional state, functional status, and additional concerns in the observation group were all significantly higher than those in the control group (P<0.05). Moreover, there was no significantly significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Conclusion  Anlotinib combined with oxaliplatin demonstrates greater clinical efficacy for treating advanced rectal cancer than bevacizumab combined with oxaliplatin, which can further prolong the median PFS of patients and improve their quality of life.